2 research outputs found
The treatment of hepatitis C: history, presence and future
The treatment of chronic hepatitis C has made remarkable progress over the
past two decades. For interferon-alpha monotherapy, sustained virological
response rates were between 2 and 9% in genotype 1 and between 16 and 23%
in genotypes 2 and 3. By adjusting treatment duration up to 48 weeks for
genotype 1 and combining regular interferon-alpha with ribavirin,
sustained response rates could be improved to 28 to 31% in genotype 1 and
around 65% in genotypes 2 and 3. Attempts to further increase efficacy
included the addition of amantadine without conclusive evidence up till
now. With the recent introduction of long-acting pegylated
interferon-alpha in combination with ribavirin, sustained virological
response rates of 8o% can be obtained in genotypes 2 and 3. However,
sustained virological response rates for patients with either genotype 1,
nonresponse to prior treatment, cirrhosis or a combination of these
characteristics are still less than 50%. In view of results with daily
high-dose interferon-alpha induction in combination with prolongation of
treatment duration up to 18 months, such patients might benefit from
induction and prolonged PEG-IFN-alpha treatment and should be treated in
an experimental setting
Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry.
BACKGROUND: Radiofrequency ablation (RFA), combined with endoscopic resection, can be used as a primary treatment for low grade dysplasia, high grade dysplasia, and early esophageal adenocarcinoma (EAC) in Barrett's esophagus (BE). The aim of the Belgian RFA registry is to capture the real-life outcome of endoscopic therapy for BE with RFA and to assess efficacy and safety outside study protocols, in the absence of reimbursement. PATIENTS AND METHODS: Between February 2008 and January 2017, data from 7 different expert centers were prospectively collected in the registry. Efficacy outcomes included complete remission of intestinal metaplasia (CR-IM), complete remission of dysplasia (CR-D), and durability of remission. Safety outcomes included immediate and late adverse events. RESULTS: 684 RFA procedures in 342 different patients were registered. Of these, 295 patients were included in the efficacy analysis, with CR-IM achieved in 88 % and CR-D in 93 %, in per-protocol analysis; corresponding rates in intention-to-treat analysis were 82 % and 87 %, respectively. Sustained remission was seen in 65 % with a median (interquartile range) follow-up of 25 (12 - 47) months. No risk factors for recurrent disease were identified. Immediate complications occurred in 4 % of all procedures and 6 % of all patients, whereas late complications occurred in 9 % of all procedures and in 20 % of all patients. CONCLUSIONS: Data from the Belgian registry confirm that RFA in combination with endoscopic resection is an efficient treatment for BE with dysplasia or early EAC. In the absence of reimbursement, more rescue treatments are used, not compromising outcome. Since there is recurrent disease after CR-IM in 35 %, surveillance endoscopy remains necessary